Sio Gene Therapies Inc Net Income per Employee (SIOX), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Sio Gene Therapies Inc   (NASDAQ: SIOX)
 

Sio Gene Therapies Inc Net Income per Employee

SIOX's Quarterly Results, Trends, Rankings, Statistics
Sio Gene Therapies Inc recorded a cumulative net loss of $-29 million during 12 month ending in the third quarter 2023.
The Healthcare sector has seen employees of 281 other companies achieving higher income per employee. While Sio Gene Therapies Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 4524.


What is Income per Employee Ratio?






SIOX Net Income per Employee (Dec 31 2022)
III. Quarter
(Sep 30 2022)
II. Quarter
(Jun 30 2022)
I. Quarter
(Mar 31 2022)
IV. Quarter
(Dec 31 2021)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -779,162 -1,358,541 -1,849,270 -1,942,892 -1,672,811
SIOX's Total Ranking # 4524 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


SIOX Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 282
Healthcare Sector # 715
Overall Market # 4524

Net Income per Employee Statistics
High Average Low
$ -779,162 $ -2,562,322 $ -6,732,081
(Dec 31 2022)   (Dec 31 2017)







Companies with similar Income per Employee for 12 month ending Dec 31 2022, within Healthcare Sector Income per Employee Income 12 month ending Dec 31 2022Number of Employees Dec 31 2022


Date modified: 2026-06-22T14:32:26+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.